Overexpression of monocarboxylate transporter 4 promotes the migration and invasion of non‑carcinogenic L929 fibroblast cells

Li,Xiangru; Zhou,Xiaoju; Liu,Ying; Fan,Jingjing; Huo,Hongjing; Yao,Jingjing; Wang,Lin; Ma,Ningning

doi:10.3892/ol.2020.12305

Overexpression of monocarboxylate transporter 4 promotes the migration and invasion of non‑carcinogenic L929 fibroblast cells

Authors:
- Xiangru Li
- Xiaoju Zhou
- Ying Liu
- Jingjing Fan
- Hongjing Huo
- Jingjing Yao
- Lin Wang
- Ningning Ma
View Affiliations

Affiliations: School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
Published online on: November 17, 2020 https://doi.org/10.3892/ol.2020.12305
Article Number: 44
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis is a primary contributor to the low survival rates of patients with cancer. Enhanced migration and invasion are two key features of the metastatic transformation of cancer cells. Furthermore, despite the fact that overexpression of the monocarboxylate transporter (MCT)1 and 4 proteins has been found to promote the migration or invasion of cancer cells, previous findings have not been conclusive and have even been contradictory. The majority of these previous studies have relied on the silencing or inhibition of MCT1/4 expression or function in highly metastatic cell lines. Silencing can be transient or incomplete, and inhibition can result in off‑target effects. Employing a different approach, the present study stably transfected human MCT1 and MCT4 into the non‑carcinogenic murine NCTC clone 929 (L929) cell line, which had undetectable endogenous MCT1 and MCT4 expression. It was observed that overexpression of MCT4, and not MCT1, promoted the migration and invasion of L929 cells. It was also found that overexpression of an inactive form of the MCT4 transporter with a single amino acid mutation failed to promote either migration or invasion, which suggested that MCT4 activity is required. Since an epidermal growth factor receptor (EGFR) inhibitor could reverse the effect of MCT4‑overexpression, it was concluded that MCT4‑overexpression exert its functions through modulating the EGF/EGFR pathway.

View Figures

View References

1	Reuben JM, Krishnamurthy S, Woodward W and Cristofanilli M: The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response. Expert Opin Med Diagn. 2:339–348. 2008. View Article : Google Scholar : PubMed/NCBI
2	Ngo H, Tortorella SM, Ververis K and Karagiannis TC: The Warburg effect: Molecular aspects and therapeutic possibilities. Mol Biol Rep. 42:825–834. 2015. View Article : Google Scholar : PubMed/NCBI
3	Halestrap AP: The monocarboxylate transporter family-Structure and functional characterization. IUBMB Life. 64:1–9. 2012. View Article : Google Scholar : PubMed/NCBI
4	Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN and Halestrap AP: CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 19:3896–3904. 2000. View Article : Google Scholar : PubMed/NCBI
5	Li Z, Wu Q and Sun S, Wu J, Li J, Zhang Y, Wang C, Yuan J and Sun S: Monocarboxylate transporters in breast cancer and adipose tissue are novel biomarkers and potential therapeutic targets. Biochem Biophys Res Commun. 501:962–967. 2018. View Article : Google Scholar : PubMed/NCBI
6	Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F and Baltazar F: Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol. 2010:4276942010. View Article : Google Scholar : PubMed/NCBI
7	Jeon JY, Lee M, Whang SH, Kim JW, Cho A and Yun M: Regulation of acetate utilization by monocarboxylate transporter 1 (MCT1) in hepatocellular carcinoma (HCC). Oncol Res. 26:71–81. 2018. View Article : Google Scholar : PubMed/NCBI
8	Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC and Baltazar F: Role of monocarboxylate transporters in human cancers: State of the art. J Bioenerg Biomembr. 44:127–139. 2012. View Article : Google Scholar : PubMed/NCBI
9	Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F and Baltazar F: Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 452:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ruan Y, Zeng F, Cheng Z, Zhao X, Fu P and Chen H: High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma. Oncol Lett. 14:5727–5734. 2017.PubMed/NCBI
11	Kim Y, Choi JW, Lee JH and Kim YS: Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: Immunohistochemical and The Cancer Genome Atlas data analyses. Hum Pathol. 46:104–112. 2015. View Article : Google Scholar : PubMed/NCBI
12	Choi JW, Kim Y, Lee JH and Kim YS: Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder. Urology. 84:245.e9–245.e15. 2014. View Article : Google Scholar
13	Gerlinger M, Santos CR, Spencer-Dene B, Martinez P, Endesfelder D, Burrell RA, Vetter M, Jiang M, Saunders RE, Kelly G, et al: Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol. 227:146–156. 2012. View Article : Google Scholar : PubMed/NCBI
14	Marchiq I and Pouysségur J: Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H⁺ symporters. J Mol Med (Berl). 94:155–171. 2016. View Article : Google Scholar : PubMed/NCBI
15	Polański R, Hodgkinson CL, Fusi A, Nonaka D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE, et al: Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 20:926–937. 2014. View Article : Google Scholar : PubMed/NCBI
16	Guan X, Bryniarski MA and Morris ME: In vitro and in vivo efficacy of the monocarboxylate transporter 1 inhibitor AR-C155858 in the murine 4T1 breast cancer tumor model. AAPS J. 21:32018. View Article : Google Scholar : PubMed/NCBI
17	Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang KY, Sasaguri Y, Nishizawa S and Kohno K: Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci. 102:1007–1013. 2011. View Article : Google Scholar : PubMed/NCBI
18	Lee JY, Lee I, Chang WJ, Ahn SM, Lim SH, Kim HS, Yoo KH, Jung KS, Song HN, Cho JH, et al: MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget. 7:43492–43503. 2016. View Article : Google Scholar : PubMed/NCBI
19	Morais-Santos F, Granja S, Miranda-Gonçalves V, Moreira AH, Queirós S, Vilaça JL, Schmitt FC, Longatto-Filho A, Paredes J, Baltazar F, et al: Targeting lactate transport suppresses in vivo breast tumour growth. Oncotarget. 6:19177–19189. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhang P, Ma J, Gao J, Liu F, Sun X, Fang F, Zhao S and Liu H: Downregulation of monocarboxylate transporter 1 inhibits the invasion and migration through suppression of the PI3K/Akt signaling pathway in human nasopharyngeal carcinoma cells. J Bioenerg Biomembr. 50:271–281. 2018. View Article : Google Scholar : PubMed/NCBI
21	Kong SC, Nøhr-Nielsen A, Zeeberg K, Reshkin SJ, Hoffmann EK, Novak I and Pedersen SF: Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells. Pancreas. 45:1036–1047. 2016. View Article : Google Scholar : PubMed/NCBI
22	Rybakovsky E, Valenzano MC, DiGuilio KM, Buleza NB, Moskalenko DV, Harty RN and Mullin JM: Improving transient transfection efficiency in a differentiated, polar epithelial cell layer. J Biomol Tech. 30:19–24. 2019. View Article : Google Scholar : PubMed/NCBI
23	Rao DD, Vorhies JS, Senzer N and Nemunaitis J: siRNA vs. shRNA: Similarities and differences. Adv Drug Deliv Rev. 61:746–759. 2009. View Article : Google Scholar : PubMed/NCBI
24	Romøren K, Thu BJ, Bols NC and Evensen Ø: Transfection efficiency and cytotoxicity of cationic liposomes in salmonid cell lines of hepatocyte and macrophage origin. Biochim Biophys Acta. 1663:127–134. 2004. View Article : Google Scholar : PubMed/NCBI
25	Yeung KT and Yang J: Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
26	Winer A, Adams S and Mignatti P: Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes. Mol Cancer Ther. 17:1147–1155. 2018. View Article : Google Scholar : PubMed/NCBI
27	Pachmayr E, Treese C and Stein U: Underlying mechanisms for distant metastasis-molecular biology. Visc Med. 33:11–20. 2017. View Article : Google Scholar : PubMed/NCBI
28	Meirson T and Gil-Henn H: Targeting invadopodia for blocking breast cancer metastasis. Drug Resist Updat. 39:1–17. 2018. View Article : Google Scholar : PubMed/NCBI
29	Sasaki S, Kobayashi M, Futagi Y, Ogura J, Yamaguchi H, Takahashi N and Iseki K: Crucial residue involved in L-lactate recognition by human monocarboxylate transporter 4 (hMCT4). PLoS One. 8:e676902013. View Article : Google Scholar : PubMed/NCBI
30	Tsai PC, Hsieh CY, Chiu CC, Wang CK, Chang LS and Lin SR: Cardiotoxin III suppresses MDA-MB-231 cell metastasis through the inhibition of EGF/EGFR-mediated signaling pathway. Toxicon. 60:734–743. 2012. View Article : Google Scholar : PubMed/NCBI
31	Shojaei F, Simmons BH, Lee JH, Lappin PB and Christensen JG: HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 320:48–55. 2012. View Article : Google Scholar : PubMed/NCBI
32	Navarini NF, Araújo VC, Brown AL, Passador-Santos F, Souza IF, Napimoga MH, Araújo NS and Martinez EF: The EGF signaling pathway influences cell migration and the secretion of metalloproteinases by myoepithelial cells in pleomorphic adenoma. Tumour Biol. 36:205–211. 2015. View Article : Google Scholar : PubMed/NCBI
33	Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL Jr and Gartenhaus RB: MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res. 65:10651–10656. 2005. View Article : Google Scholar : PubMed/NCBI
34	Payen VL, Hsu MY, Rädecke KS, Wyart E, Vazeille T, Bouzin C, Porporato PE and Sonveaux P: Monocarboxylate transporter MCT1 promotes tumor metastasis independently of its activity as a lactate transporter. Cancer Res. 77:5591–5601. 2017. View Article : Google Scholar : PubMed/NCBI
35	Majumder A, Ray S and Banerji A: Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells. Mol Cell Biochem. 452:111–121. 2019. View Article : Google Scholar : PubMed/NCBI